About

Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.

Articles

Everything in Moderation: Investigating the U-Shaped Link Between HDL Cholesterol and Adverse Outcomes

Citation:

US Cardiology Review 2019;13(1):49–53

Novel Pharmacologic Treatments for Cardiovascular Disease: A Practical Update

Citation:

US Cardiology Review 2017;11(2):98–104.

Dyslipidemia: Current Therapies and Guidelines for Treatment

Citation:

US Cardiology Review 2017;11(1):10–5

Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Inhibition in Patients With or at High Risk of Coronary Heart Disease

Citation:

US Cardiology Review 2017;11(1):16–7